BioVie Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BIVI Nasdaq 2830 bioviepharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioVie Inc.

BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population - Sep 15th, 2026 8:15 am
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - Sep 15th, 2026 5:30 am
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid - Sep 14th, 2026 2:01 pm
BioVie’s lead therapy candidate shows improvement in key long COVID symptoms - Sep 10th, 2026 8:27 am
Dow closes sharply lower as oil surge fuels inflation fears - Sep 8th, 2026 8:10 am
BioVie advances Parkinson’s Phase 3 development program with FDA engagement - Sep 8th, 2026 7:52 am
BioVie Announces Update to Parkinson’s Phase 3 Development Program - Sep 8th, 2026 5:30 am
BioVie completes final patient visit in Phase 2 Long COVID trial - Aug 31st, 2026 7:05 am
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - Aug 31st, 2026 6:00 am
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Aug 14th, 2026 7:00 am
Parkinson's drug developers are betting big on inflammation - Aug 7th, 2026 11:13 am
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results - Aug 7th, 2026 7:00 am
BioVie stock sinks on Phase IIb Parkinson’s trial data - Aug 7th, 2026 5:05 am
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim - Aug 6th, 2026 7:03 am
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease - Aug 6th, 2026 5:30 am
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial - Aug 5th, 2026 10:18 am
BioVie: Long COVID trial fully enrolled – ICYMI - May 29th, 2026 2:30 pm
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - May 29th, 2026 7:00 am
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 - May 27th, 2026 6:00 am